CBD for Individuals at Risk for Alzheimer's Disease
This study is testing if cannabidiol (CBD) can help people with Mild Cognitive Impairment (MCI), a condition that can be a step towards Alzheimer's disease. Researchers want to see if CBD improves markers of Alzheimer's progression, thinking abilities, sleep, pain, anxiety, and body stress. You could be eligible if you are between 55 and 85 years old and have a diagnosis of MCI. The study is comparing two types of CBD (Full Spectrum CBD and Broad Spectrum CBD) against a placebo (an inactive substance) to see which, if any, are effective. The main goals are to measure changes in thinking abilities and Alzheimer's disease markers over 24 weeks. The current status of this study is unclear.
- Study design
- This is a double-blind, randomized controlled trial, meaning neither you nor your study doctor will know if you are receiving CBD or a placebo. It plans to include 236 participants.
- What's involved
- If you are eligible, you will be randomly assigned to receive one of the study conditions for 24 weeks. Your neurocognitive function and Alzheimer's disease progression markers will be measured at the beginning and end of this 24-week period.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progress will be monitored for 24 weeks while you are receiving the study intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
CBD for Individuals at Risk for Alzheimer's Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Neurocognitive FunctionWeek 0 to Week 24
The following assessments will be used to inform an aggregate measure of neurocognitive function: * The Clinical Dementia Rating Scale is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias. Higher scores indicate worse cognitive impairment. * NIH-Toolbox Cognitive Battery (NIH-TB CB) assessments are used to detect and measure specific aspects of cognition, including crystallized intelligence, psychomotor function, executive function, attention, and working memory. * Rey Auditory Verbal Learning Test to evaluate working memory and the Digit Symbol Substitution Task to evaluate global cognitive operations. * Montreal Cognitive Assessment (MoCa) * Functional Activities Questionnaire (FAQ) will be used to measure changes in dementia risk over the course of the clinical trial.
- Biomarkers of Alzheimer's Disease ProgressionWeek 0 to Week 24
* Changes in plasma levels of N-p-tau181 will be measured in ng/dl. * Changes in plasma Aβ42/Aβ40 ratio will be measured in ng/dl. * Changes in plasma Neurofilament Light (Nfl) will be measured in ng/dl.